SecBot SecBot
SECBOTREPLAY Home › Report › PYXS

PYXS · Pyxis Oncology reported financial results for 2025 and provided a…

Pyxis Oncology · PRESS-RELEASE filed Mar 23, 2026 at 07:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 23, 2026 at 07:00 ET

Pyxis Oncology reported financial results for 2025 and provided a clinical update on its lead asset, micvotabart pelidotin (MICVO), in head and neck cancer. The company completed enrollment in its Phase 1 monotherapy dose expansion study and expects updated data mid-2026. Preliminary data showed strong response rates, but revenues declined year-over-year due to lower milestone and royalty income. The company has sufficient cash to fund operations into Q4 2026.

  • Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in Q1 2026
  • Preliminary monotherapy data: 46% ORR and 92% DCR in 13 efficacy-evaluable patients
  • Combination with KEYTRUDA®: 71% ORR and 100% DCR in 7 patients
  • Revenues decreased to $13.9M in 2025 from $16.1M in 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access